KBP Biosciences PTE. Ltd. (“KBP Biosciences” or the “Company”), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced that KBP is a proud corporate supporter of the Kidney Disease Clinical Trialists 2025 Workshop held in Washington DC, April 4-5, 2025. Invited speaker Fred Yang PhD, Chief Development Officer at KBP, presented industry perspective in the session of “Estimands in Kidney Disease Trials” focused on  “Estimands in Clinical Trials for Safety Evaluation”.

 

“KBP will continue to work with physicians and patients to find the best treatment options for patients with CV and CKD disease,” said Dr. Zhenhua Huang, the executive chairman of KBP. 

Photo from KDCT meeting place: